Longevity Therapeutics: The Involvement of EDA2R, the “Self-Destruction Gene”
Therapeutics · 02.06.2026 · 3 (2) · 14
DOI: 10.3390/therapeutics3020014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutics, online erschienen am 02.06.2026. Verfasst von Renad I. Zhdanov und 1 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Plasma Ectodysplasin A2 Receptor (EDA2R) has emerged as one of the most robust tissue-agnostic biomarkers of biological aging, and importantly, appears to be causally involved in “inflammaging”—the chronic low-grade inflammation that drives age-related decline—rather than merely reflecting it [...]
Zitieren
APA
Zhdanov, R. I., & Düzgüneş, N. (2026). Longevity Therapeutics: The Involvement of EDA2R, the “Self-Destruction Gene”. Therapeutics, 3(2), 14. https://doi.org/10.3390/therapeutics3020014
Vancouver
Zhdanov RI, Düzgüneş N. Longevity Therapeutics: The Involvement of EDA2R, the “Self-Destruction Gene”. Therapeutics. 2026;3(2):14. doi:10.3390/therapeutics3020014
BibTeX
@article{Zhdanov2026,
author = {Zhdanov, Renad I. and Düzgüneş, Nejat},
title = {Longevity Therapeutics: The Involvement of EDA2R, the “Self-Destruction Gene”},
journal = {Therapeutics},
year = {2026},
volume = {3},
number = {2},
pages = {14},
doi = {10.3390/therapeutics3020014}
}
EUVIMED